Status: Recruiting
Phase Ib/II Clinical Study of QLS1304 Combined With Endocrine Therapy in the Treatment of ER+/HER2- Breast Cancer Patients
This study is a multi-center, open label, phase Ib/II clinical trial aimed at evaluating the safety, preliminary efficacy characteristic and PK characteristics of QLS1304 in combined with endocrine therapy in ER+/HER2- breast cancer patients. This study was divided into two stages: combo dose escalation and dose expansion.
Participants needed: 300
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Qilu Pharmaceutical Co., Ltd.Updated: May 22, 2026Locations: 1
Eligibility criteria
Volunteer to participate in this study, sign an informed consent form and have g... [+10]
Subjects have received live or attenuated live vaccines within 4 weeks before th... [+10]